Furthermore, IgM‐enriched preparations of IVIg (IgM‐IVIg) showed improved efficacy in reducing bacteraemia in animal models of pneumonia and sepsis [26, 27] and have progressed to clinical trials with improved outcome reported in specific patient sub‐groups [28, 29, 30]. The gene discussed is CD40LG; the disease is susceptibility to pneumonia measurement.